Product Description
Oxacillin is a semisynthetic penicillinase-resistant and acid-stable penicillinwith an antimicrobial activity. Oxacillin binds to penicillin-binding proteins in the bacterial cell wall, thereby blocking the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to inhibition of cell growth and causes cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxacillin)
Mechanisms of Action: PBP Inhibitor,Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Austria | Brazil | Bulgaria | China | Colombia | Czech | Dominican Republic | Ecuador | Estonia | France | Germany | India | Latvia | Lithuania | Morocco | Peru | Philippines | Romania | Russia | Singapore | Slovenia | Taiwan | Tunisia | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|